Dr. Ami C. Milton

Fabian Mendoza is a Rheumatologist in Bala Cynwyd, Pennsylvania. Dr. Mendoza is rated as a Distinguished provider by MediFind in the treatment of Scleroma. His top areas of expertise are Systemic Sclerosis (SSc), Scleroderma, Scleroma, and Rheumatoid Arthritis (RA). Dr. Mendoza is currently accepting new patients.

Dr. Wigley received his M.D. degree from the University of Florida College of Medicine. He completed an internship and residency at Johns Hopkins where he also trained in a postdoctoral fellowship program. Dr. Wigley is a physician-scientist whose specialty is Raynaud’s phenomenon and scleroderma. He founded The Johns Hopkins Scleroderma Center with Robert A. Wise, M.D., of the Johns Hopkins Division of Pulmonary Medicine. Dr. Wigley has been honored with two American College of Rheumatology awards over the past couple years. He received the ACR Distinguished Clinician Scholar Award in 2009 and the ACR Masters Award in 2011. Dr. Wigley is rated as a Distinguished provider by MediFind in the treatment of Scleroma. His top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Raynaud Phenomenon, and Scleroma.

Dr. Ami Shah is an Associate Professor of Medicine and Director of the Division of Rheumatology at the Johns Hopkins University School of Medicine. Dr. Shah also serves as the Co-Director of the Johns Hopkins Scleroderma Center. Her areas of clinical expertise include rheumatology, particularly scleroderma and Raynaud's phenomenon. She is a graduate of the Massachusetts Institute of Technology and Johns Hopkins University School of Medicine. She completed her internal medicine residency training at Stanford University Hospital & Clinics and rheumatology post-doctoral fellowship at Johns Hopkins. During her fellowship training, she earned her Master of Health Science in Clinical Investigation at the Johns Hopkins Bloomberg School of Public Health. Dr. Shah’s clinical practice is focused on the broad spectrum of patients with scleroderma and related disorders, and her expertise includes management of complications such as Raynaud’s phenomenon, digital ischemia, pulmonary hypertension, cardiac dysfunction, myopathy, aggressive skin disease and concomitant cancer. Dr. Shah teaches post-doctoral fellows in her clinic about the evaluation and management of scleroderma. Dr. Shah’s research program has focused on the interface between cancer and autoimmunity in scleroderma, myositis and the newly emerging area of immune-related adverse events due to immune checkpoint inhibitor therapy. In highly collaborative studies, her group has published seminal observations linking cancer with the development of autoimmunity in scleroderma, with implications for cancer screening strategies in this population and the potential to shed insight into the pathogenesis of paraneoplastic rheumatic disease. In addition to her work in cancer and autoimmunity, Dr. Shah has an active research program in other clinical and therapeutic aspects of scleroderma, including early detection of cardiopulmonary complications and improving outcome measures and therapeutics for Raynaud's phenomenon. Dr. Shah also directs rheumatology precision medicine initiatives through the Johns Hopkins Individualized Health (inHealth) Initiative. The division’s program seeks to harness technological resources for comprehensive data collection and harmonization, strengthen novel data analytic approaches including defining unique patient subgroups, and accelerate the incorporation of discoveries into the delivery of clinical care. Dr. Shah has been a recipient of the ACR Research and Education Foundation Clinical Investigator Fellowship Award. In 2018, her research contributions were recognized at the 5th Systemic Sclerosis World Congress with receipt of the Edith Busch Prize for Young Investigators. In 2020, she was honored to receive the prestigious Henry Kunkel Young Investigator Award from the American College of Rheumatology. She is a member of the American College of Rheumatology. Dr. Shah is rated as an Advanced provider by MediFind in the treatment of Scleroma. Her top areas of expertise are Scleroderma, Scleroma, Systemic Sclerosis (SSc), and Scleredema.